Prise en charge des cancers thyroïdiens localisés de souche vésiculaire différenciée

Bull Cancer. 2024 Oct;111(10S1):10S19-10S30. doi: 10.1016/S0007-4551(24)00405-3.
[Article in French]

Abstract

The incidence of follicular-derived thyroid cancers has increased worldwide in recent decades, mainly papillary thyroid cancers at low recurrence risk. A process of de-escalation in the initial management and follow-up of these patients has therefore been implemented in parallel. This article provides the best practice recommendations made by the French learned societies (Société française d'endocrinologie, Société française de médecine nucléaire, Association française de chirurgie endocrine, Société française d'oto-rhino-laryngologie et de chirurgie de la face et du cou), european and international learned societies (European Society for Medical Oncology and the American Thyroid Association), in the management of follicular-derived thyroid cancer without distant metastases. The extent of thyroid surgery and lymph node dissection, strategies of radioiodine ablation, follow-up protocols and the management of excellent prognosis papillary cancers ≤ 10 mm will be addressed.

Keywords: Cancer thyroïdien papillaire; Deescalation; Désescalade; Irathérapie; Lobectomie; Lobectomy; Papillary thyroid cancer; Radioiodine; Risk stratification; Risque évolutif; Thyroïdectomie; Total thyroidectomy.

Publication types

  • English Abstract
  • Practice Guideline

MeSH terms

  • Adenocarcinoma, Follicular* / pathology
  • Adenocarcinoma, Follicular* / therapy
  • Carcinoma, Papillary / pathology
  • Carcinoma, Papillary / therapy
  • Humans
  • Iodine Radioisotopes* / therapeutic use
  • Lymph Node Excision
  • Prognosis
  • Thyroid Cancer, Papillary / pathology
  • Thyroid Cancer, Papillary / therapy
  • Thyroid Neoplasms* / pathology
  • Thyroid Neoplasms* / therapy
  • Thyroidectomy
  • Tumor Burden

Substances

  • Iodine Radioisotopes